An Interview With...
Franco Negron
CEO
Simtra
In this interview, we spoke with Franco Negron, CEO of Simtra, about how the company is advancing its position as a premier CDMO for sterile injectables while preparing for the next wave of complex biologics. Negron discusses Simtra’s balanced expertise across high‑volume GLP‑1s and high‑potency modalities like ADCs, its strategic partnerships to reduce supply chain complexity, and its coordinated U.S. and European expansions designed to enhance global resilience and support reliable, scalable production.
Simtra has positioned itself as a premier CDMO for sterile injectables, including complex modalities like GLP-1 agonists and ADCs. What differentiates Simtra’s approach to injectable manufacturing in such a competitive and rapidly advancing space?
Simtra’s ability to support both high volume injectable products like GLP1s and highly complex, lower volume modalities such as ADCs gives us a uniquely balanced expertise across the sterile injectables landscape. While GLP1s are sometimes described as “complex,” their main challenge is the requirement for cold chain storage after production; relative to other biologics, they do not require toxicity related containment or lyophilization for stability. ADCs, by contrast, demand specialized handling, containment, and technical sophistication. Our strength across this full range enables us to execute reliably regardless of modality, and it positions us to serve customers as their pipelines evolve from early stage, high complexity assets to mature, large-scale commercial products.
This balance also creates the kind of portfolio diversity that matters deeply to our customers. Clients want to know that their CDMO partner is stable, invested for the long term, and not overly dependent on one or two products or customers. At Simtra, our diversified product mix helps us maintain a “warm base” with consistent manufacturing activity, experienced talent, and ready capacity, so we can support our customers whenever they need us. This operational stability is a core part of the value we bring: a dependable partner with the continuity, capability, and foresight to support programs throughout their lifecycle.
How can partnerships and collaborations help CDMOs like Simtra reduce supply chain complexity and deliver more complete solutions for customers?
Simtra’s approach to partnerships and collaborations is grounded in focus. We have intentionally concentrated our investments on sterile injectables fill/finish, building capabilities that span drug product development through commercial manufacturing. This allows us to deliver deep expertise, consistent execution, and scalable capacity in the area where we create the most value for customers.
At the same time, we recognized that the broader drug manufacturing supply chain includes upstream and downstream services beyond our core. Rather than attempting to replicate those capabilities in-house, we collaborate with best-in-class strategic partners across areas such as
drug substance production, device assembly, secondary packaging and distribution. Through aligned processes, shared standards, information sharing and streamlined workflows, these partnerships reduce supply chain complexity, minimize handoffs and accelerate timelines. For our customers, this model provides a more seamless, reliable path to market without sacrificing expertise or focus.
Simtra is expanding its presence in both the U.S. and Europe. How do matched North American and EU capabilities strengthen customers’ supply chain resilience and support global commercialization strategies?
Geographic redundancy has become increasingly critical as customers seek greater supply chain continuity, regional flexibility and protection from geopolitical or regulatory disruptions. Simtra is addressing these needs through a deliberate dual-site strategy in the United States and Germany, with closely matched capabilities across both regions.
By 2027, both locations will offer high-potency vial manufacturing, prefilled syringe production and standard injectable capabilities to support growing demand for complex products such as ADCs, GLP-1s and other biologics. In the U.S., we are making significant investments in Bloomington, Indiana, including the addition of a new building with two prefilled syringe lines and a vial line with lyophilization capacity at our existing site. We have also acquired an additional 65-acre campus nearby with a 300,000 square foot building that will further expand high-potency capabilities and provide space for client-dedicated lines.
Together, our U.S. and European sites are designed to support one another as demand evolves or disruptions occur, providing built-in redundancy across continents. For customers, this strategy delivers the flexibility, confidence and resilience needed to scale therapies globally and maintain reliable supply throughout the product lifecycle.
The injectable market is undergoing a major transformation, driven by GLP-1s, biologics, and next-generation therapeutics. How is Simtra preparing its facilities and technical workforce to meet these emerging demands?
As injectable products become more complex and demand accelerates, driven by GLP1s, biologics, and next generation therapeutics, Simtra is preparing both its facilities and its technical workforce to support customers with greater speed and reliability. A key part of this preparation is engaging earlier in the drug product development process to eliminate tech transfer risk and build manufacturability from the start.
Our “Product Design with the End in Mind” approach focuses on making deliberate technical choices, such as formulation strategy, lyophilization cycles, and container selection, that support robust scaleup, minimize product loss, and maximize yield. This work is enabled by tightly integrated scientific, development, and manufacturing teams that operate side by side and share insights in real time.
At the same time, we are investing in facilities and talent to support the next wave of injectable products, ensuring the right capacity, technologies, and specialized expertise are in place as programs advance. Customers work with the same project manager throughout the lifecycle, maintaining continuity and clarity from development through commercial launch. Together, this integration of people, processes, and infrastructure allows us to move programs efficiently from lab through launch while meeting the demands of an evolving injectable landscape.
Simtra has invested heavily in expanding sterile fill-finish and lyophilization capacity in Bloomington and Halle. Can you walk us through the key technologies and containment strategies you are implementing—such as isolator-based lines, high-potency handling, and lyophilization scale-up—to support complex products like ADCs and other potent biologics?
Simtra’s recent expansions in Bloomington and Halle are designed to support the growing demand for complex and highly potent injectable products through advanced automation and isolator technology.
In Halle/Westfalen, Germany, a new building inaugurated in July 2025, adds two highspeed isolator lines which includes one for prefilled syringes and one dedicated to highly potent vial manufacturing. In the U.S., we are expanding in Bloomington, Indiana, with a new building coming online this year that features three new commercial scale isolator lines, along with a new campus that will introduce a commercial scale highly potent vial line in 2027. Collectively, these investments add two new commercial scale high potency vial lines, one in Halle (with four lyos) and one in Bloomington (with three lyos), significantly strengthening our global ADC manufacturing capabilities. These will complement our existing 5 HiPo vial lines in Halle (2 clinical scale, 3 commercial scale).
A key technical enhancement is the integration of advanced lyophilization technologies, including controlled nucleation on the new highly potent vial line in Bloomington. This capability enables more consistent ice crystal formation, improved drying efficiency, and greater process robustness, critical factors for complex biologics. Together, these technologies reflect Simtra’s continued commitment to safe, flexible, and scalable platforms that allow customers to confidently advance potent injectable therapies from development through commercial production.
From your perspective as CEO, what trends or challenges do you see shaping the injectable CDMO landscape over the next few years, and how is Simtra positioning itself to stay ahead of them?
The injectable CDMO landscape is increasingly shaped by a shift toward more localized manufacturing “in the region, for the region.” Customers are prioritizing shorter, more resilient supply chains and placing greater emphasis on reducing handoffs between vendors, particularly for complex sterile products.
This is driving a greater reliance on integrated CDMO partnerships that can support development, manufacturing, and supply planning in a more connected way. At the same time, AI is being embedded across development, manufacturing, and supply planning to improve coordination and decision‑making.
Against this backdrop, success is being defined less by efficiency alone and more by supply continuity and the ability to get medicines to patients. Simtra is aligning its strategy accordingly, focusing on integrated, regionally based manufacturing models designed to support reliable, uninterrupted supply.